Infectious Diseases – Global Clinical Trial Landscape (2018-2023)

The 21st century has witnessed significant outbreaks of infectious diseases, impacting public health, health security, biodefense, and the global economy. From SARS in 2002 to the ongoing fight against COVID-19 and recent cases of Monkeypox, the need for rapid prevention and control measures against epidemic viruses is evident. The global clinical trial landscape for infectious diseases has seen a substantial increase over the past five years, with around 7,000 industry-initiated studies worldwide, evenly distributed between the Asia-Pacific (APAC) and Western regions, reflecting a global effort to develop medical knowledge and prevent infectious diseases. In addition, APAC is also noted to not just stand out in the number of studies, but also in patient recruitment efficiency.

Overall, infectious disease clinical trials have expanded rapidly, with a high compound annual growth rate (CAGR) from 2018 to 2022. The number of trials increased from over 700 in 2018 to more than 1,000 by 2022, demonstrating a commitment to holistic solutions. Mainland China, the EU5 countries, and the United States have become major hubs for infectious disease research and clinical trials.

While small molecules have traditionally dominated these studies, biologic medicines are gaining ground. Vaccines and monoclonal antibodies, as well as advanced technologies like mRNA and siRNA therapeutics, show promise. Vaccine research and development are global, with the United States, China, and Europe at the forefront.

In conclusion, the global clinical trial landscape for infectious diseases has evolved significantly in recent years, with the COVID-19 pandemic driving research efforts and highlighting the importance of global collaboration in combating infectious diseases. Gain in-depth insights into infectious diseases-based clinical trials and be better informed about trends, regional disparities, technological advancements, and financing dynamics by downloading the report below.